+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anticonvulsants Market Research Report by Drug types (AMPA, Barbiturate, and Benzodiazepine), Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5336339
  • Report
  • April 2022
  • Region: United States
  • 107 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbott Laboratories
  • Biocon Limited
  • GlaxoSmithKline PLC
  • Lundbeck A/S
  • Merck KGaA
  • Novo Nordisk A/S
The United States Anticonvulsants Market size was estimated at USD 2,080.58 million in 2021, USD 2,371.96 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.44% to reach USD 3,776.38 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Anticonvulsants to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug types, the market was studied across AMPA, Barbiturate, Benzodiazepine, Carbamate Anticonvulsants, Carbonic Anhydrase Inhibitor, Dibenzazepine, and Triazine.
  • Based on Application, the market was studied across Anxiety, Bipolar Disorder, Borderline Personality Disorder., Epilepsy, Fibromyalgia, Migraine, and Neuropathic Pain.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anticonvulsants Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Anticonvulsants Market, including Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Eisai Co., Ltd. by Royalty Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., GW Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lundbeck A/S, Mankind Pharma Ltd, Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical, Pfizer Inc., Sanofi S.A, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Anticonvulsants Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Anticonvulsants Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Anticonvulsants Market?
4. What is the competitive strategic window for opportunities in the United States Anticonvulsants Market?
5. What are the technology trends and regulatory frameworks in the United States Anticonvulsants Market?
6. What is the market share of the leading vendors in the United States Anticonvulsants Market?
7. What modes and strategic moves are considered suitable for entering the United States Anticonvulsants Market?
Frequently Asked Questions about the U.S. Anticonvulsants Market

What is the estimated value of the U.S. Anticonvulsants Market?

The U.S. Anticonvulsants Market was estimated to be valued at $2080.6 Million in 2021.

What is the growth rate of the U.S. Anticonvulsants Market?

The growth rate of the U.S. Anticonvulsants Market is 10.4%, with an estimated value of $3776.4 Million by 2027.

What is the forecasted size of the U.S. Anticonvulsants Market?

The U.S. Anticonvulsants Market is estimated to be worth $3776.4 Million by 2027.

Who are the key companies in the U.S. Anticonvulsants Market?

Key companies in the U.S. Anticonvulsants Market include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Eisai Co., Ltd. by Royalty Pharma, GlaxoSmithKline PLC and GW Pharmaceuticals PLC.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Biocon Limited
  • GlaxoSmithKline PLC
  • Lundbeck A/S
  • Merck KGaA
  • Novo Nordisk A/S

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Anticonvulsants Market, by Drug types
6.1. Introduction
6.2. AMPA
6.3. Barbiturate
6.4. Benzodiazepine
6.5. Carbamate Anticonvulsants
6.6. Carbonic Anhydrase Inhibitor
6.7. Dibenzazepine
6.8. Triazine
7. Anticonvulsants Market, by Application
7.1. Introduction
7.2. Anxiety
7.3. Bipolar Disorder
7.4. Borderline Personality Disorder.
7.5. Epilepsy
7.6. Fibromyalgia
7.7. Migraine
7.8. Neuropathic Pain
8. California Anticonvulsants Market9. Florida Anticonvulsants Market10. Illinois Anticonvulsants Market11. New York Anticonvulsants Market12. Ohio Anticonvulsants Market13. Pennsylvania Anticonvulsants Market14. Texas Anticonvulsants Market
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbott Laboratories
16.2. Astrazeneca PLC
16.3. Bausch Health Companies Inc.
16.4. Biocon Limited
16.5. Cadila Pharmaceuticals Limited
16.6. Cipla, Inc.
16.7. Eisai Co., Ltd. by Royalty Pharma
16.8. GlaxoSmithKline PLC
16.9. Glenmark Pharmaceuticals Ltd.
16.10. GW Pharmaceuticals PLC
16.11. Johnson & Johnson Services, Inc.
16.12. Lundbeck A/S
16.13. Mankind Pharma Ltd
16.14. Merck KGaA
16.15. Novartis AG
16.16. Novo Nordisk A/S
16.17. Otsuka Pharmaceutical
16.18. Pfizer Inc.
16.19. Sanofi S.A
16.20. Sunovion Pharmaceuticals Inc.
16.21. Takeda Pharmaceutical Company Limited
16.22. Teva Pharmaceutical Industries Ltd.
16.23. Wockhardt Limited
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES ANTICONVULSANTS MARKET: DYNAMICS
FIGURE 2. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2021 VS 2027 (%)
FIGURE 3. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2027
FIGURE 5. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY AMPA, 2019-2027 (USD MILLION)
FIGURE 6. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY AMPA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 7. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, 2019-2027 (USD MILLION)
FIGURE 8. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 9. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, 2019-2027 (USD MILLION)
FIGURE 10. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 11. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 20. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2027
FIGURE 22. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ANXIETY, 2019-2027 (USD MILLION)
FIGURE 23. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2019-2027 (USD MILLION)
FIGURE 29. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, 2019-2027 (USD MILLION)
FIGURE 33. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2019-2027 (USD MILLION)
FIGURE 35. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 36. UNITED STATES ANTICONVULSANTS MARKET: FPNV POSITIONING MATRIX
FIGURE 37. UNITED STATES ANTICONVULSANTS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 38. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ANTICONVULSANTS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES ANTICONVULSANTS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY AMPA, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY STATE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY STATE, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES ANTICONVULSANTS MARKET: SCORES
TABLE 20. UNITED STATES ANTICONVULSANTS MARKET: BUSINESS STRATEGY
TABLE 21. UNITED STATES ANTICONVULSANTS MARKET: PRODUCT SATISFACTION
TABLE 22. UNITED STATES ANTICONVULSANTS MARKET: RANKING
TABLE 23. UNITED STATES ANTICONVULSANTS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 24. UNITED STATES ANTICONVULSANTS MARKET: MERGER & ACQUISITION
TABLE 25. UNITED STATES ANTICONVULSANTS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 26. UNITED STATES ANTICONVULSANTS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 27. UNITED STATES ANTICONVULSANTS MARKET: INVESTMENT & FUNDING
TABLE 28. UNITED STATES ANTICONVULSANTS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 29. UNITED STATES ANTICONVULSANTS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Astrazeneca PLC
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Eisai Co., Ltd. by Royalty Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • GW Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical
  • Pfizer Inc.
  • Sanofi S.A
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
Note: Product cover images may vary from those shown

Loading
LOADING...